Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
Status:
Not yet recruiting
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
Our goal is to show that in hypertensive men and women with left ventricular hypertrophy
(LVH) treatment with a mineralocorticoid receptor (MR) antagonist, versus a thiazide-like
diuretic, will improve coronary microvascular function and cardiac efficiency, which will
associate with improvements in LV structure and function. We will achieve this through a
randomized, controlled, basic experimental study involving humans (BESH).